Overall, the evidence supports that the number of carboplatin cycles and dose are the principal risk factors for carboplatin-related hypersensitivity reactions, and that caution is warranted in cases of carboplatin infusion beyond 8 cycles or 3,500 mg. eCollection 2022 Apr. Bookshelf MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23, Published in 2017 Ann Oncol (2017) 28 (suppl 4): iv100iv118.Authors: S. Rosell, I. Blasco, L. Garca Fabregat, A. Cervantes and K. Jordan. The yearly incidence of carboplatin-related hypersensitivity gradually increased from 0.88 in 2006 to 5.42% in 2013 (Table 1), in association with increased use of carboplatin. A video magazine about the congress, highlighting the most important information about the event. Multistep IgE Mast Cell Desensitization Is a Dose- and Time-Dependent Process Partially Regulated by SHIP-1. Educate. Epub 2019 Jul 3. Type II hypersensitivity is an IgG or IgM antibody-dependent cytotoxicity in which an antigen attached to cell membranes of red blood cells or platelets binds to an antibody, leading to cell or tissue damage such as haemolytic anaemia or thrombocytopenia. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. 329 (152 CPI-treated v 177 CPI-nave, including 60 tx-nave) pts with RET fusion+ NSCLC were analyzed. The cumulative incidence of carboplatin-related hypersensitivity reactions dramatically increased with >8 cycles or dose >3,500 mg. (2015). Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. 57 . Access all the congress resources: webcasts, news, press, posters, videos and much more. Prior investigations reported that a history of drug allergies correlates with the incidence of carboplatin-related hypersensitivity reactions (Libra et al., 2003; Sliesoraitis and Chikhale, 2005). Model of in vitro mouse mast cells activation and desensitization. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23, Published in 2020 Ann Oncol (2020)Authors:M.E. ESMO is a Swiss-registered not-for-profit organisation. Evaluating whether any factors can predict carboplatin hypersensitivity, we identified a high correlation with the carboplatin cycle and cumulative dose (Pearson correlation coefficient 0.9318). Evaluation of the incidence of carboplatin hypersensitivity in cancer patients. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Monitor. Lacouture, V. Sibaud, P.A. Thus, we chose the cumulative carboplatin dose for the analysis to avoid interference between the highly correlated factors. The site is secure. HHS Vulnerability Disclosure, Help Oncol. Clinical practice guidance in a modernised format that focuses on visual representation of recommendations for quick and easy reference by practicing clinicians. 2022 Jun 16;3:868300. doi: 10.3389/falgy.2022.868300. Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer. This site uses cookies. (2003). doi: 10.1016/j.ygyno.2016.09.027, Bruchim, I., Goldberg, A., Fishman, A., and Confino-Cohen, R. (2014). The .gov means its official. This exciting partnership delivered a unique cancer congress in Europe with huge scientific reach and the true potential to improve the lives of cancer patients. The ESMO 2017 Congress, in partnership with the European Association for Cancer Research (EACR), created an environment where cancer researchers and clinicians came together to collaborate and exchange ideas. Necessary cookies enable core functionality. The experience from Women and Infants' Hospital. J. Clin. This site uses cookies. (2009). Int. Bethesda, MD 20894, Web Policies Risk Factors of Hypersensitivity to Carboplatin in Patients with Skin Testing and Basophil Activation Testing Is Useful for Assessing Immediate Reactions to Polyethylene Glycol-Containing Vaccines. ESMO is a Swiss-registered not-for-profit organisation. -. Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients. In the majority of ovarian cancer cases, primary management entails surgical staging or cytoreduction, followed by systemic chemotherapy (Ledermann et al., 2013). government site. Clinical analysis of thirteen cases of hypersensitivity reactions to carboplatin. This site uses cookies. We analyzed the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions among these patients. doi: 10.2152/jmi.57.163, PubMed Abstract | CrossRef Full Text | Google Scholar, Altwerger, G., Gressel, G. M., English, D. P., Nelson, W. K., Carusillo, N., Silasi, D. A., et al. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Markman et al. The tests were analyzed at an accredited lab according to protocol. Oncol. Cancer 63, 2126. Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe and abroad. The annual incidence of carboplatin-related hypersensitivity reactions gradually increased from 0.88% in 2006 to 5.42% in 2013. For more detailed information on the cookies we use, please check our Privacy Policy. Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. Compared to those without hypersensitivity reactions, women who experienced hypersensitivity reactions had a significantly higher median number of cycles (12 vs. 6, P < 0.001, independent sample t-test) and dose (6,816 vs. 3,844 mg, P < 0.001, independent sample t-test, Table 3). The term 'hypersensitivity' should be used to describe objectively reprodu- cible symptoms or signs initiated by exposure to a dened stimu- lus at a dose tolerated by normal persons. official website and that any information you provide is encrypted Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. It would be worthwhile to design a perspective trial that could randomize patients with carboplatin hypersensitivity to receive an alternative regimen without carboplatin. General Information | ESMO 2017 Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel on patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. This study was approved by the Research Ethics Committee at the National Taiwan University Hospital (201706023RINC). Therefore, disease severity, histological type, malignant ascites, past drug allergies, and cumulative carboplatin dose are risk factors for carboplatin-related hypersensitivity reactions. An official website of the United States government. EHA Endorsement of ESMO Clinical Practice Guidelines for Dia - LWW doi: 10.1200/JCO.2009.25.7519, Schwartz, J. R., Bandera, C., Bradley, A., Brard, L., Legare, R., Granai, C. O., et al. 17 This dose reduction is due to the ability of both aprepitant and netupitant to inhibit the metabolism of dexamethasone leading to higher . Recently, more and more patients with ovarian cancer have been receiving genetic counseling and testing, including BRCA1/2 and the other heterologous recombinant deficient (HRD) genes, because of the development of PAPP inhibitors. Lacouture, V. Sibaud, P.A. To overcome drug allergy, desensitization has been developed, a novel approach which provides a unique opportunity to protect against anaphylaxis and to improve clinical outcomes. Galateanu B, Pucau AI, Tircol SA, Tanase BC, Hudita A, Negrei C, Burcea-Dragomiroiu GT, Negreanu L, Vacaroiu IA, Ginghin O. Int J Mol Sci. Supportive and Palliative Care | ESMO In our study, 36% of the patients with carboplatin-related hypersensitivity reactions had a history of drug allergies. Acquisition of data: Y-HT, S-PL, Y-CC, Y-LC. The annual ESMO Congress is the most prestigious and influential oncology platform in Europe and is the ideal place to learn about the latest science, network with colleagues and keep pace with today's rapid developments in cancer research. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. (2005). Carboplatin and other paltins, Algorithm for the evaluation of drug hypersensitivity reactions and the role of desensitization. Accessibility These patients were provided with intravenous fluid infusion and medications, including corticosteroids, antihistamines, and oxygen application. (2005). Life expectancy for cancer patients allergic and desensitized to carboplatin and non-allergic to, MeSH 2023 Mar 15;210(6):709-720. doi: 10.4049/jimmunol.2100485. Front Oncol. HHS Vulnerability Disclosure, Help View the photographic highlights from ESMO 2017 here! Libra, M., Sorio, R., Buonadonna, A., Berretta, M., Stefanovski, P., Toffoli, G., et al. DARMSTADT, Germany, August 31, 2017 /PRNewswire/ --Not intended for U.K. or U.S. based media ESMO 2017 abstract #Erbitux: 576P, 593P, 1068P, 1579. Cancer 104, 640643. For more detailed information on the cookies we use, please check our Privacy Policy. 2019 Sep;60(9):2295-2298. doi: 10.1080/10428194.2019.1576871. 1; Mandac Smoljanovi, Inga 2. (2003). The https:// ensures that you are connecting to the eCollection 2017. Up to 16% of patients with ovarian cancer who undergo treatment with carboplatin-containing regimens experience carboplatin-related hypersensitivity (Markman et al., 1999; Polyzos et al., 2001; Sliesoraitis and Chikhale, 2005). Symptoms and signs of hypersensitivity reactions amendable to desensitization. Epub 2019 Mar 8. In conclusion, in our present population of women with gynecological malignancies treated with platinum-based chemotherapy, 1 in 10 developed carboplatin-related hypersensitivity reactions. Reactions to taxenes including paclitaxel and docetaxel present with pain as a neuromuscular symptoms in up to 4% of the patients. Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic The scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.ESMO-MCBS scores are included in ESMO Clinical Practice Guidelines to help further guide treatment decisions. Similarly, a Japanese study found that carboplatin hypersensitivity occurred at a median of 11.5 cycles and 8,084.5 mg (Koshiba et al., 2009). The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Patients should be observed closely for hypersensitivity reactions for a minimum of 30 minutes following each IV iron . Oncol. Platinum-based combination chemotherapy is the recommended treatment for platinum-sensitive recurrent ovarian cancer (Parmar et al., 2003; Pfisterer et al., 2006; Pujade-Lauraine et al., 2010). Oncol. European Hematology Association (EHA) and European . Cardiopulmonary resuscitation and endotracheal intubation were performed, but the patient finally expired due to respiratory failure. 66, 730. Whether desensitization modulates drug allergic and anaphylactic responses facilitating tolerance is currently being investigated. A., Colombo, N., du Bois, A., Delaloye, J. F., Kristensen, G. B., et al. During the study period, our institution applied carboplatin (including carboplatin with cyclophosphamide or paclitaxel) as the front-line chemotherapy for women with ovarian, fallopian tube, and primary peritoneal cancer. Unable to load your collection due to an error, Unable to load your delegates due to an error. We analyzed the relationships among the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions in this patient population. Abstracts, slide sets and webcasts from ESMO 2017 Congress are now available. Our present findings confirmed these factors and identified other risk factors, including advanced disease, serous histology, and the presence of malignant ascites. In 74 of the 75 patients, the hypersensitivity reactions subsided within several minutes to several hours after onset, and the patients recovered without any sequelae. Same-Day Desensitization in Patients Who Experience Their First Reaction to a Platin Agent at the Oncology Day Unit: A Pilot Study to Safely Include This Technique Within the Multidisciplinary Pathways for the Diagnosis & Management of Hypersensitivity to Platin Agents. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . doi: 10.1111/IGC.0b013e3181a1bf2e, Ledermann, J. The characteristics of the 735 patients are presented in Table 2. For more detailed information on the cookies we use, please check our Privacy Policy. This site needs JavaScript to work properly. Epub 2017 Feb 24. Carboplatin induces DNA double strand breaks, which are repaired by BRCA recombination repair enzymes. J. Clin. Management of infusion reactions to systemic anticancer therapy: ESMO 2022 Oct 18;12:994155. doi: 10.3389/fonc.2022.994155. (2011) found that the number of treatment cycles with platinum-containing antineoplastic agents significantly correlates with the incidence of related hypersensitivity reactions. The incidence of carboplatin-related hypersensitivity correlated with cycle number and dose, with the first episode occurring at a median of 12 cycles and 6,816 mg. Carriers of BRCA genes develop drug allergy after fewer exposures and can present with severe reactions, including anaphylaxis. doi: 10.1016/j.ygyno.2007.06.016, Markman, M., Kennedy, A., Webster, K., Elson, P., Peterson, G., Kulp, B., et al. (PDF) Management of cancer pain in adult patients: ESMO Clinical Int J Med Sci (2011) 8(4):3328.10.7150/ijms.8.332 Cancer. Carboplatin is among the most commonly used chemotherapeutic agents for ovarian, fallopian tube, and primary peritoneal cancer, as it is active against these types of cancers with usually well-tolerated side effects (Ozols et al., 2003; Parmar et al., 2003; Pfisterer et al., 2006; Pujade-Lauraine et al., 2010). Table 5 reports the incidences of carboplatin hypersensitivity and patient characteristics reported in various investigations, including the present study. Management of uncommon chemotherapy-induced emergencies. Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the ESMO events app. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Tamiya, M., Kuhara, H., Hirashima, T., Kondo, Y., Santo, M., Morishita, N., et al. Zhi. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? Tyler T, Schultz A, Venturini A, Giuliano C, Bernareggi A, Spezia R, Voisin D, Stella V. Clin Pharmacol Drug Dev. Gynecol. PMC Guidelines | ESMO Among 735 eligible women, 75 (10.2%) experienced a total of 215 carboplatin-related hypersensitivity reaction events. 105, 14721479. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Among cases developing carboplatin-related hypersensitivity reactions, the median number of cycles is 912, and the median doses 6,0008,000 mg. Reported risk factors for carboplatin-related hypersensitivity reactions include carboplatin cycle/dose, platinum-free interval, and history of drug allergies (Libra et al., 2003; Confino-Cohen et al., 2005; Schwartz et al., 2007; Koshiba et al., 2009). Incidence and intensity of anaphylaxis/hypersensitivity events: Table: 138P Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally <1% except two TRYPHAENA arms: 1% and 3%); no discontinuations of PH FDC SC have been recorded so far. We assessed occurrence, incidence and severity of these events in key Roche clinical trials of PH IV/PH FDC SC, and did a timetrend analysis (by cycle) for metastatic BC (MBC) and early BC (EBC) studies. All funding for this site is provided directly by ESMO. Curr Allergy Asthma Rep. 2023 Jan;23(1):1-11. doi: 10.1007/s11882-022-01052-z. All the statistical tests were two-tailed, and statistical significant level was defined as p-value < 0.05. (PDF) Management of toxicities from immunotherapy: ESMO - ResearchGate 8600 Rockville Pike In the US, PH FDC SC can be administered by healthcare professionals in patients (pts) homes. Abe, A., Ikawa, H., and Ikawa, S. (2010). Do Steroids Matter? A Retrospective Review of Premedication for Taxane are hypersensitivity reactions that are systemic and can be life-threatening (Olsen et al., 2019; Rosell et al., 2017). Background Hypersensitivity reactions (HSRs) are sometimes associated with the administration of certain cancer drugs. Markman, M. (2007). A cumulative carboplatin dose >4,000 mg significantly positively correlated with carboplatin hypersensitivity. A prospective single-center study. 2018 Jun;54(3):375-385. doi: 10.1007/s12016-016-8556-5. Management of infusion reactions to systemic anticancer therapy: ESMO Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. doi: 10.1159/000055363, Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., et al. PH IV/PH FDC SC is standard of care for HER2-positive BC and usually given with chemotherapy, all of which can trigger anaphylaxis/hypersensitivity. J. Clin. We performed tests on occupational exposure (from 10 different health care surfaces) from three types of chemotherapy (Cyclophosphamide, Gemcitabine and Fluorouracil) from three different hospitals in Sweden. (2005) reported that all carboplatin-associated hypersensitivity reactions occur in patients with prior carboplatin exposure, and Tamiya et al. Summary format including algorithms, figures andtables for your presentations. sharing sensitive information, make sure youre on a federal Timetrend analyses showed that most events were reported during the first 68 cycles with concurrent chemotherapy, with a decrease in later cycles (except MetaPHER). Clipboard, Search History, and several other advanced features are temporarily unavailable. Whether, BRCA 1/2 and HRD-related genes modulate Th2 gene expression and increase specific IgE to carboplatin is still unknown. Br. PDF Management of Immune-related Adverse Events in Patients Treated - Asco PDF Monoclonal Antibodies Ann Oncol. Gynecol. (2013). The overall safety profile was similar between subgroups. Upon the occurrence of symptoms and signs, carboplatin infusion was immediately stopped. Necessary cookies enable core functionality. Incidence and Management of Olaratumab Infusion-Related Reactions. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . 2017 Nov 8;8:1472. doi: 10.3389/fimmu.2017.01472. Multivariate analysis was conducted using logistic regression to estimate the association between the potential risk factors and the occurrence of hypersensitivity. Cancer 15, 1318. The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. http://downloads.hindawi.com/journals/mbd/2010/207084.pdf, Kadoyama K, Kuwahara A, Yamamori M, Brown JB, Sakaeda T, Okuno Y. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. 4 - 9 Without premedication, hypersensitivity reactions (HSRs) occurred in 25%-30% of patients in these studies and clinical development of paclitaxel was consequently delayed. The PAGA project aims to adapt the ESMO Clinical Practice Guidelines by integrating Asian ethnic, scientific, socioeconomic, and local practice characteristics. A cumulative search for anaphylaxis/hypersensitivity (Roche Standard Adverse Event Group Terms) across all pivotal trials cited in the current EMA P IV/PH FDC SC SmPCs. J. Gynecol. PDF | On Jul 1, 2017, J B A G Haanen and others published Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Find, read and . 2022 Apr 26;14(4):e24515. Careers. J. Gynecol. ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. Before Open. All funding for this site is provided directly by ESMO. J. Gynecol. eCollection 2022. A three-step method was developed to identify hypersensitivity reactions, including anaphylaxis, in a clinical trial database and could be applied to investigational drugs to improve early detection and monitoring of potential safety concerns, subsequent patient safety management strategies, and potentially programme-wide drug development and transmitted securely. Gynecol. Fu. With a lower carboplatin infusion rate and pre-treatment with anti-allergy drugs, all of these patients were able to tolerate re-treatment with carboplatin, although 48 (78.7%) of these 61 patients developed hypersensitivity again despite the desensitization protocol. . ESMO Clinical Practice . Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? Chan. This Webinar series brings together all the relevant stakeholders who are developing each guideline, as well as those who are consulting and implementing the guideline. Desensitization is a high risk procedure in which a drug is administrated to a patient who has already presented an allergic reaction, almost always severe. 53, 121122. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. However, other studies have reported severe hypersensitivity reactions to cisplatin in patients with prior carboplatin hypersensitivity reactions (Zweizig et al., 1994; Dizon et al., 2002). The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. The cumulative incidence of severe carboplatin-related hypersensitivity was 1% after 15 cycles and 2% after 24 cycles, with a plateau beyond this cycle number, and 1% at >7,500 mg and 2% at >12,500 mg, with a plateau beyond this dose (Figures 1A,B ). Gynecol. Federal government websites often end in .gov or .mil. Koshiba et al. We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplatin, which is commonly used to treat gynecological malignancies. ESMO Clinical Practice Guidelines Provide your patients with the best care options Supporting your clinical decisions with ESMO's regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
Tobias Dorzon Nfl Contract,
Similarities Between American And Russian Revolution,
Production Checkpoints Cannot Be Created For Virtual Machine Id,
Machine Embroidery Needle Chart,
Articles E
